Notizia - Recent Pharma, Healthcare and Biotech Happenings

Juno Therapeutics recently acquired Redox Therapies and it’s vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist. The upfront consideration for the Redox Therapies acquisition was $10 million in cash. UK-based Cell Medica expands its T cell immunotherapy program with the acquisition of privately-held Delenex Therapeutics Evelo Biosciences, US based Microbiome Company working in oncology through characterization of cancer associated bacteria, and Epiva Biosciences, another microbiome company from Flagship VentureLabs, merged to create a leading immuno-microbiome platform company in the U.S. Medivation Inc., an American biopharmaceutical company...